CARDIFF ONCOLOGY, INC. Commercial Paper
CARDIFF ONCOLOGY, INC. (CRDF) had Commercial Paper of $8.49 million as of 2016-09-30, per its 10-Q filed 2016-11-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current
us-gaap:CommercialPaper · last filed 2016-11-09
- 2016-09-30: Commercial Paper $8.49M.
- 2016-06-30: Commercial Paper $11.97M.
| Period end | Commercial Paper |
|---|---|
| 2016-09-30 | $8.49M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $11.97M 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |